Global Antiemetics Market Size By Type (5-HT3 receptor antagonists, Dopamine antagonists), By Application (Chemotherapy, Motion sickness), By Region, And Segment Forecasts, 2023 to 2032

The Global Antiemetics Market was valued at USD 6.1 billion in 2023 and is projected to surpass USD 9.4 billion by 2031, growing at a CAGR of 5.5% during the forecast period from 2023 to 2031. The increasing incidence of gastrointestinal disorders, side effects of chemotherapy, post-operative nausea, and morning sickness during pregnancy are key factors driving demand for antiemetic drugs. The rising elderly population, expanding access to oncology care, and growing adoption of combination antiemetic therapies further contribute to market growth. Additionally, ongoing advancements in drug delivery systems and targeted formulations are enhancing therapeutic efficacy, creating favorable prospects for market expansion.

Drivers:

1. Rising Chemotherapy Procedures:

The growing number of cancer patients undergoing chemotherapy, where nausea and vomiting are common side effects, is a primary driver. Antiemetics are integral to supportive oncology care, particularly serotonin receptor antagonists and neurokinin-1 receptor antagonists.

2. Increasing Incidence of Motion Sickness and Gastrointestinal Disorders:

A rise in travel-related motion sickness and disorders like gastroenteritis, vertigo, and cyclic vomiting syndrome is fueling demand for over-the-counter and prescription antiemetic products globally.

3. Technological Innovations in Drug Delivery:

New formulations such as orally disintegrating tablets, transdermal patches, and subcutaneous injectables are improving patient compliance and expanding usage across different demographics and clinical settings.

Restraints:

1. Side Effects and Drug Interactions:

Prolonged use of certain antiemetics can result in adverse effects including dizziness, sedation, or cardiac complications. These risks limit their long-term use, especially among vulnerable populations such as pregnant women and the elderly.

2. Patent Expirations and Generic Competition:

The expiration of patents for key branded drugs has led to the influx of generic versions, reducing overall profit margins and discouraging innovation in certain segments.

Opportunity:

1. Expansion in Emerging Markets:

Rising healthcare spending and improved access to medical services in Asia-Pacific, Latin America, and parts of Africa present substantial growth opportunities for antiemetics, particularly in oncology and maternal health.

2. Development of Multimodal Therapies:

Combination treatments that address multiple pathways of nausea (e.g., 5-HT3, NK1, and dopamine antagonists) are gaining traction, offering companies scope to develop integrated antiemetic regimens.

Market by System Type Insights:

By system type, the Serotonin Receptor Antagonists (5-HT3 antagonists) segment led the global antiemetics market in 2023. This dominance is due to their efficacy in managing chemotherapy-induced nausea and vomiting (CINV), with drugs such as ondansetron and granisetron being widely prescribed. The segment is anticipated to retain its leading position throughout the forecast period, supported by continued demand from oncology centers and post-operative care.

Market by End-Use Insights:

In 2023, the Hospitals & Clinics segment accounted for the largest share of the market, exceeding 45% in revenue contribution. This is driven by institutional use of antiemetics for surgical recovery, chemotherapy, and emergency gastrointestinal treatment. The Retail Pharmacies segment is also growing rapidly due to consumer demand for OTC motion sickness and pregnancy-related nausea treatments.

Market by Regional Insights:

North America led the global antiemetics market in 2023, owing to advanced healthcare infrastructure, high cancer prevalence, and access to reimbursed therapies. However, Asia-Pacific is expected to witness the highest growth rate during the forecast period, bolstered by a growing population base, increasing awareness of gastrointestinal health, and expanding access to cancer treatment services.

Competitive Scenario:

Key players in the global antiemetics market include GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc., Novartis AG, Merck & Co., Inc., Teva Pharmaceuticals, Eisai Co., Ltd., Sanofi S.A., and Cipla Ltd. These companies are focused on R&D for next-generation antiemetic therapies, geographic expansion, and strategic partnerships. Notable developments include:

2023: Pfizer launched a dual-action antiemetic targeting serotonin and dopamine receptors for improved post-operative recovery.

2024: Eisai received regulatory approval for a new oral antiemetic formulation with extended-release properties for use in cancer clinics.

2025: Novartis entered a strategic agreement with a biotech firm to develop a first-in-class NK1 antagonist for acute gastrointestinal disorders.

Scope of Work – Global Antiemetics Market

Key Market Developments:

Pfizer Inc. introduced a fixed-dose antiemetic combination targeting multiple pathways for enhanced efficacy in chemotherapy patients (2023).

Eisai Co., Ltd. launched a novel transdermal patch antiemetic in Japan and the U.S. for patients with swallowing difficulties (2024).

GlaxoSmithKline plc expanded its maternal care portfolio in 2025 with a new prescription antiemetic designed specifically for pregnancy-related nausea.

FAQs:

1) What is the current market size of the Global Antiemetics Market?

The market was valued at USD 6.1 billion in 2023.

2) What is the major growth driver of the Global Antiemetics Market?

The major growth driver is the rising number of chemotherapy procedures and associated supportive care needs.

3) Which is the largest region during the forecast period in the Global Antiemetics Market?

North America is currently the largest region, but Asia-Pacific is expected to grow at the fastest rate.

4) Which segment accounted for the largest market share in the Global Antiemetics Market?

The Serotonin Receptor Antagonists (5-HT3 antagonists) segment held the largest share in 2023.

5) Who are the key market players in the Global Antiemetics Market?

Key players include GlaxoSmithKline, Pfizer, Johnson & Johnson, Novartis, Merck, Teva, Eisai, and Sanofi.